Start on the road to a healthier you with the 21-Day Intermittent Fasting Challenge for only $19 – WSLS 10

Hows that New Years Resolution to lose weight coming along? We get it. Most of us have been there. Shedding the pounds while keeping yourself happy and healthy is no easy task. Sure there are alternatives bariatric surgery or laser treatments to name a couple. But why not try a method that does not require going under the knife and is inexpensive? The 21 Day Intermittent Fasting Challenge could be what you need to succeed in your weight loss journey.

So what exactly is Intermittent Fasting? Essentially its just what the name implies. Its an eating pattern that cycles between periods of fasting and eating. It doesnt specify which foods you should eat but rather when you should eat them. Not only can it help you lose weight and visceral fat, but it has also been known to reduce the blood levels of insulin in your body while increasing the human growth hormone levels. It has been shown to improve blood pressure and triglycerides, reduce the risk of cancer, and help to prevent Alzheimers, among other benefits.

Ad

This 21 Day Intermittent Fasting Challenge gets you started on the road to a healthier you. You will receive a meal plan that includes 2 meals and one snack daily, plus an overview of what food you can and should not eat. You will learn about potential side effects and how to avoid them, plus be introduced to a variety of fasting methods. You can customize your intake depending on your diet of choice there are Keto, vegan, Paleo, vegetarian, and Vegan Keto plan options available.

Best of all, you will not be doing this alone. Once you sign on, you will become part of an exclusive community of like-minded people from all around the world with whom you will be able to share your successes, ask questions, or look for guidance.

So stop procrastinating. By doing this challenge, and pairing it with a good exercise program, you could be very pleasantly surprised by the results. Get lifetime access to the 21 Day Intermittent Fasting Challenge for only $19, an 80% discount off the regular suggested retail price.

Ad

Prices subject to change.

Continue reading here:

Start on the road to a healthier you with the 21-Day Intermittent Fasting Challenge for only $19 - WSLS 10

Protein Therapeutics Market Report 2023 Market SWOT Analysis, Key Indicators, Forecast 2027. – Digital Journal

Market Overview

The Global Protein Therapeutics Market is expected to cross USD 290,691.88 Million by 2027 at a CAGR of 6.86%.

Market Dynamics

One of the most important classes of pharmaceuticals is therapeutic protein therapies. These medications are used to treat and manage a variety of conditions, including cancer and infectious infections. Protein therapeutic medicines offer a great deal of promise to improve human health, thus demand for these treatments is expected to skyrocket in the future. During the projected period, the increased prevalence of chronic diseases such as diabetes is expected to have an impact on the protein therapies markets growth. Rapid technological breakthroughs in the field of protein therapies are expected to have a beneficial impact on demand. During the forecast period, increased awareness of protein therapies is expected to fuel the global protein therapeutics markets growth. Protein therapeutics market growth is expected to be boosted in the near future by the increased use of plasma-derived medicines for the treatment of chronic diseases. Increased government measures to strengthen the healthcare sector are projected to create favourable conditions for the protein therapies market to grow.

During the projected period, however, the tight regulatory environment governing product approval is expected to restrain the growth of the protein therapies market. Protein treatments market expansion is projected to be constrained by their high cost.

Sample Report: https://www.marketresearchfuture.com/sample_request/10142

Segmental Analysis

The market for protein therapeutics has been divided into three categories: type, application, and end user.

Monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormone, follicle-stimulating hormone, and others are among the products available. Because of the rising prevalence of diabetes around the world, the insulin segment is the fastest-growing.

The worldwide protein therapies market has been divided into cancer, metabolic diseases, immunologic disorders, haematological disorders, and others based on application. Because of the increased frequency of cancer around the world, the cancer segment accounts for a substantial portion of the worldwide protein therapies market.

The global protein therapies market has been divided into hospitals and clinics, specialty centres, and others based on the end user. During the projected period, the hospitals and clinics segment is expected to develop due to an increase in hospital admissions and the increased prevalence of chronic diseases.

Regional Overview

During the review period, the Americas was the largest regional market. The demand for therapeutic proteins is expanding as a result of increased government initiatives and growing concerns about healthcare workers health and safety. Moreover, one of the primary factors driving the protein therapies market over the forecast period is the increased prevalence of cancer. With such a big patient population, the global protein therapies market is expected to increase significantly in the near future.

During the forecast period, the western European healthcare market, which includes Germany, the United Kingdom, France, and Italy, is expected to see an increase in healthcare expenditure, as well as an increase in cases of rheumatoid arthritis, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy, resulting in the growth of the protein therapeutics market. During the forecast period, it is expected to enhance the growth of the protein therapies market.

The fastest-growing geographical market is Asia-Pacific. Emerging market participants in previously untouched regions, increased R&D in the protein therapeutics segment, the governments increased focus on immunisation to avoid various diseases, and a large target population are all factors impacting market expansion. One of the primary factors driving the regions protein therapies market growth is the expanding elderly population.

The expansion of the protein therapeutics market in the Middle East and Africa is likely to be fueled by government efforts and increased investments in the healthcare sector in the UAE and South Africa.

Access Report Details @ https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142

Competitive Dynamics

The notable players of the market are Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co., Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc. (US), Sanofi (France), and Biogen, Inc. (US).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Get More Related Reports:

https://www.marketresearchfuture.com/reports/women-healthcare-market-3121

https://www.marketresearchfuture.com/reports/big-data-pharmaceutical-advertising-market-1014

https://www.marketresearchfuture.com/reports/enema-based-products-market-4370

https://www.marketresearchfuture.com/reports/dermabrasion-market-4702

https://www.marketresearchfuture.com/reports/cancer-biologic-therapy-market-566

Contact:

Market Research Future

99 Hudson Street,5Th Floor

New York, New York 10013

United States of America

Phone:

+1 628 258 0071(US)

+44 2035 002 764(UK)

Email: [emailprotected]

Excerpt from:

Protein Therapeutics Market Report 2023 Market SWOT Analysis, Key Indicators, Forecast 2027. - Digital Journal

Grieving mom wants true account of how son died training as SEAL – centraljersey.com

Editors note: The author of this Your Turn guest column is Regina Mullen, whose son, Kyle Mullen, 24, a native of Manalapan and a graduate of Manalapan High School, died earlier this year while he was training to become a U.S. Navy SEAL. Regina Mullen is seeking a full account of what happened to her son.

By Regina Mullen

Democracy and freedom are founded on an informed public. I would like the public to be made aware of the U.S. Navy SEALs medical negligence.

Unfortunately, due to my son Kyle Mullens passing, I am learning of other atrocities and cover-ups that have been going on for years.

The American public and the government should care about the fate of men who courageously risk their lives to defend this great nation. The public needs to demand an independent investigation by the government and report the findings to the congressional committee that oversees the military.

Immunity should be offered in order to induce SEAL cooperation and the investigation would be a means for truth and to hold those responsible accountable for their actions.

Substantial recommendations to the U.S. Department of Defense and to Congress should be submitted for consequences and reform.

Please continue reading this column to see a letter Congressman Andy Kim (D-NJ), who is a member of the House of Representatives Armed Services Committee, has sent to Sean ODonnell, the acting inspector general of the U.S. Department of Defense, requesting an immediate inspector general investigation into the death of my son, a Navy SEAL candidate who died hours after completing Hell Week.

My son was found on the barracks floor by a 19-year-old non-medical sailor. Kyle did not die in a hospital as the media continually states inaccurately.

Another SEAL candidate was sent to the hospital that day, Feb. 4, 2022, in critical condition. That individual was intubated and treated for severe pneumonia, which is what I believe Kyle also had.

The Navy to this date has yet to reveal Kyles autopsy results, which is another concerning matter.

In his letter to ODonnell, Congressman Kim states, As a member of the House Armed Services Committee, I write to you today out of deep concern and sadness over the tragic death of New Jersey resident and Navy SEAL candidate Kyle Mullen.

Kyle was only 24 years old when he died waiting for medical attention in San Diego justhours after finishing the Hell Week portion of the SEAL selection process.

I strongly urge and respectfully request that you immediately initiate a full and thorough investigation into the incident involving Kyle Mullen and the circumstances that led to his death.

Its my understanding there were multiple warning signs, but candidate Mullen was notoffered comprehensive nor consistent medical treatment.

I am deeply concerned by allegations that multiple calls for assistance went unanswered and that officers and instructors may have encouraged and facilitated the use of steroids and Human Growth Hormone for recovery, Kim wrote.

Kyle, his family, friends and community deserve to know the truth about what happened on that day. The entire country deserves to know and trust that we treat our men and women in uniform, including those that are vying for elite positions to serve their country, with the utmost professionalism, dignity, decency and highest quality of care at all times. Anything less is unacceptable.

While I am aware there is a Navy investigation underway into Kyles death, I feel it entirely appropriate to launch an independent Inspector General investigation as well and I encourage you to leave no stone unturned.

Steps should be taken to ensure there is no retaliation against anyone for participating in the investigation. Moreover, no officers nor instructors, regardless of rank, ought to be shielded from accountability or allowed to avoid investigation through assignment changes or retirement.

I also ask that you share any and all outcomes of that investigation with Kyles family and the public so there is accountability for any individuals that bear responsibility. It goes without saying that a single death during a training exercise is one too many and that our military families deserve better, Kim wrote to ODonnell.

As things stand now, the SEALs investigate themselves. This is absurd. There is no doubt that without Congresss involvement, both through oversight and administering the investigation itself, there will be no chance of reform.

I am encouraging members of the public and all military personnel those who are currently serving and those who are veterans to call, write and/or email members of Congress, senators, etc., to not only provide their own stories, but to demand an immediate investigation. I hope we can help to save young mens lives in the future.

Regina Mullen is the mother of Kyle Mullen.

View original post here:

Grieving mom wants true account of how son died training as SEAL - centraljersey.com

Healthy Month of Ramadan: Benefits of fasting – Scoop Empire

The holy month of Ramadan is all about fasting and endurance of everyday life while abstaining from all foods and drinks. There are so many reasons why Muslims fast during Ramadan. But other than the obvious religious and spiritual reasons, fasting was always attributed to many health benefits. In this new day and age, we have science-backed research to prove said health benefits. But, what are they? And how does fasting aid them?

Weight loss, delay aging, and muscle gain are all goals for all of us. Who doesnt want the perfect build or waist measurements! Well, all of those come easily during Ramdan since fasting helps with all of them. When it comes to weight loss, research has found that whole-day fasting could reduce body weight by up to 9% and significantly decrease body fat over 1224 weeks, it was also found that it is more effective than calorie restriction, especially at increasing fat loss while simultaneously preserving muscle tissue which is a hard balance to achieve, gym-goers know that for a fact. This is also connected to increasing HGH or human growth hormone which leads to growth, metabolism, weight loss, and muscle strength. A study in 11 healthy adults showed that fasting for 24 hours significantly increased levels of HGH. Which will automatically help with muscle growth and complete rejuvenation of the body.Delaying aging however is still in the works to be proven. Studies on rats showed that fasting every other day increased their longevity in living by 83% which is very promising if proven generally.

Fasting does wonders to our internal systems and metabolism, so much so that it affects every bodily system altogether. When it comes to the Cardiovascular System it is a common fact that a healthy balanced diet helps reduce the risk of getting heart disease. A study showed that eight weeks of alternate-day fasting reduced levels of bad LDL cholesterol and blood triglycerides by 25% and 32%. Another study showed that 110 obese adults showed that fasting for three weeks under medical supervision significantly decreased blood pressure, as well as levels of blood triglycerides, total cholesterol, and bad LDL cholesterol. All of these decreased numbers are vital to keeping our hearts and vascular system healthy and fasting is key to achieving that.

Another major system that scientists are trying to connect improvement to fasting is the nervous system and mental health. And while research on this particular system is limited to animal testing, a study on mice found that practicing intermittent fasting for 11 months improved both brain function and brain structure up to the point where it can prevent neurodegenerative disorders and protect against conditions such as Alzheimers disease and Parkinsons.

All and all there is still so much research to be conducted in many fields and ways to get to the bottom of this. One thing is for sure, no matter what you fast for whether its health or religion. The benefits are undeniable. And depending on the type of fasting you choose which there are many youll definitely get the desired results if you can just keep on it and endure it for a set amount of time.

Excerpt from:

Healthy Month of Ramadan: Benefits of fasting - Scoop Empire

Prader-Willi Syndrome Market to Exhibit Healthy Growth Rate till 2032, Investigates DelveInsight | Key Companies Millendo Therapeutics, Levo…

DelveInsights Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prader-Willi Syndrome Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Prader-Willi Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Prader-Willi Syndrome: An Overview

According to US National Library of Medicine, Prader-Willi syndrome is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity.

Although considered a rare disorder, PWS is one of the most common conditions seen in genetic clinics and is the most common genetic cause of obesity that has been identified to date.

Prader-Willi Syndrome Market Key Facts

As per Foundation for Prader-Willi Syndrome (PWS) Research, the disease occurs in approximately one out of every 15,000 births

It affects males and females with equal frequency and affects all races and ethnicities.

The estimates place the incidence between 1 in 10,000-30,000 individuals in the general population, while as per Adult Prader-Willi Syndrome: An Update on Management by Luk Ho-Ming, the incidence is about 1 in 15,00025,000 live births.

According to DelveInsights estimation, the total prevalent cases of Prader Willi syndrome (PWS) were found to be approx. 47,000 in the 7 Major Markets in the year 2017.

Prader-Willi Syndrome Market

The Prader-Willi Syndrome Market Size is expected to experience a positive shift during the study period owing to the launch of upcoming therapies. The therapies under development are focused on novel approaches that will improve the disease condition.

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Prader-Willi Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Prader-Willi Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Prader-Willi Syndrome Epidemiology

The epidemiology section covers insights into the historical and current Prader-Willi Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Prader-Willi Syndrome Epidemiology Subtype Segmentation

Prevalent cases of Prader Willi Syndrome

Diagnosed cases of PWS

Prader Willi Syndrome (PWS) cases by Mutation types

Prader Willi Syndrome (PWS) associated clinical Manifestation

Prader-Willi Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prader-Willi Syndrome market or expected to get launched in the market during the study period. The analysis covers Prader-Willi Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Reports Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Prader-Willi Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in various stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report https://www.delveinsight.com/sample-request/prader-willi-syndrome-market

Prader-Willi Syndrome Therapeutics Analysis

Currently, there is no cure for PWS. The lives of individuals with PWS can be improved with an early diagnosis and careful management of symptoms but more effective therapies are needed. The treatment of PWS is currently based on treating the symptoms of the disorder as they arise. Growth hormone deficiency is present in almost all children and many adults with PWS. In multiple studies, human growth hormone (HGH) has been found to be beneficial for those with Prader-Willi syndrome.

Some of the key companies in the Prader-Willi Syndrome Market include:

Millendo Therapeutics

Levo Therapeutics

Harmony Biosciences

Soleno Therapeutics

And many more.

Prader-Willi Syndrome Therapies covered in the report include:

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies https://www.delveinsight.com/sample-request/prader-willi-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary

3. Prader-Willi Syndrome Competitive Intelligence Analysis

4. Prader-Willi Syndrome Market Overview at a Glance

5. Prader-Willi Syndrome Disease Background and Overview

6. Prader-Willi Syndrome Patient Journey

7. Prader-Willi Syndrome Epidemiology and Patient Population

8. Prader-Willi Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Prader-Willi Syndrome Unmet Needs

10. Key Endpoints of Prader-Willi Syndrome Treatment

11. Prader-Willi Syndrome Marketed Products

12. Prader-Willi Syndrome Emerging Therapies

13. Prader-Willi Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Prader-Willi Syndrome Market Outlook (7 major markets)

16. Prader-Willi Syndrome Access and Reimbursement Overview

17. KOL Views on the Prader-Willi Syndrome Market.

18. Prader-Willi Syndrome Market Drivers

19. Prader-Willi Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report https://www.delveinsight.com/sample-request/prader-willi-syndrome-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Metrorrhagia Market

DelveInsights Metrorrhagia Market report delivers an in-depth understanding of the historical and forecasted epidemiology, the Metrorrhagia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.

Media ContactCompany Name: DelveInsight Business ResearchContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/

See the original post:

Prader-Willi Syndrome Market to Exhibit Healthy Growth Rate till 2032, Investigates DelveInsight | Key Companies Millendo Therapeutics, Levo...

Growth Hormone Treatment – Children's Hospital of …

GH is sold under a number of different prescription brand names, but all of them contain the same medication. Which brand name your child will use, and the shape and color of the pen that delivers the medication, will depend upon your medical insurance.

Because GH is very expensive, Childrens Hospital works with insurance reimbursement specialists to determine which brand will be covered under your medical insurance. Within 2 to 4 weeks after your child has been prescribed HG treatment, an insurance reimbursement specialist will call your home. It is very important that you speak with the specialist please pick up or return the call! Your childs prescription will not be filled until you have spoken with the reimbursement specialist. You should receive your childs GH with 2 to 4 weeks after approval; if you havent heard from the reimbursement specialist after 4 weeks, call the Endocrinology Clinic.

If your insurance changes during the course of GH treatment, please notify the Endocrinology Clinic as soon as possible or the continuity of your childs treatment could be interrupted.

See the original post:

Growth Hormone Treatment - Children's Hospital of ...

A World Without Dwarfism: what is new drug featured in Ellie Simmonds BBC show, and is it available in the UK? – NationalWorld

Former Paralympic swimmer Ellie Simmonds said she met many amazing people while making the documentary

Paralympian swimmer Ellie Simmonds OBE will front a new BBC documentary exploring a drug that claims to make children with dwarfism grow closer to average height.

A BBC documentary exploring a drug that claims to make children with dwarfism grow closer to average height is to air this evening (Tuesday 5 April).

The show is presented by Paralympian swimmer Ellie Simmonds OBE, who was diagnosed with achondroplasia - the most common form of dwarfism - as a baby.

Simmonds has said she is pretty much against use of the drug, called vosoritide, but takes an open-minded approach during the documentary and meets families in the UK and the US who say the drug could improve their lives.

So, what is dwarfism, what is vosoritide, and how can you watch the Ellie Simmonds documentary.

Heres what you need to know.

What is dwarfism?

Restricted growth, sometimes known as dwarfism, is a condition characterised by unusually short height, according to the NHS.

There are 2 main types of restricted growth; proportionate short stature, which is a general lack of growth in the body, arms and legs, and disproportionate short stature, where the arms and legs are particularly short.

Some people with restricted growth also have other physical problems, such as bowed legs or an unusually curved spine, but most people dont have any other serious problems and are able to live a relatively normal life and have a normal life expectancy.

The most common cause of proportionate short stature is being born to small parents, but it is also sometimes the result of the body not producing enough growth hormone.

A rare genetic condition called achondroplasia is the most common cause of disproportionate short stature.

It does not always run in the family and many children with achondroplasia have parents of normal height.

What is vosoritide?

Vosoritide is a new drug that has been developed to treat children with achondroplasia.

Makers claim that it can reduce some of the medical complications associated with dwarfism, if given to children while they are still developing. They also claim that it can make children taller.

It is in the final stages of trials in the UK, but it could be decided as early as next year whether or not to make it available on the NHS.

It is already available in the US, with treatment costing around $350,000 a year, or around 266,866.25.

Who is Ellie Simmonds?

Ellie Simmonds, aged 27, is a British former Paralympian swimmer who has won eight Olympic medals, and five of them are gold.

She has competed in the 2008, 2012, 2016 and 2020 Paralympics.

When she was 13-years-old, she became the youngest British swimmer to have ever competed at the Paralympics, and is also the youngest person to have ever received an OBE, which was given to her when she was aged 14.

Simmonds, who is from Walsall in the West Midlands, also won the BBCs young sports personality of the year award at the age of 14.

In September 2021, she announced her Paralympic retirement after missing out on a medal in the Tokyo 2020 Paralympics.

Simmonds is also a patron of the Dwarf Sports Association UK, a sporting charity which aims to make sporting opportunities accessible to everyone of restricted growth in the UK.

What has Ellie Simmonds said about the documentary?

During the documentary, Simmonds talks about her own experiences and asks wider questions about the relationship between science, diversity and disability.

She will meet other members of the dwarfism community and speak to her own family about her own experiences of growing up with achondroplasia.

Simmonds said: This is a subject close to my heart. Growing up these drugs werent available to me and had they been, I dont know what my parents would have done.

But I wouldnt change myself. I love who I am and I am glad that I have dwarfism because I think my body is strong and beautiful.

Speaking about the documentary on her official Twitter page, she said she was bursting with excitement.

Ellie Simmonds: A World Without Dwarfism? will air on BBC One & iPlayer on Tuesday 5th April at 9pm.

I learnt so so much from this documentary & journey and met so many amazing people along the way. Cant believe its going to be out for all to watch!

When is the documentary on TV?

Ellie Simmonds: A World Without Dwarfism? is on BBC One at 9pm on Tuesday 5 April 2022.

The hour-long documentary is available to watch live on television, or on BBC iPlayer.

Follow this link:

A World Without Dwarfism: what is new drug featured in Ellie Simmonds BBC show, and is it available in the UK? - NationalWorld

Tree of Health Medicine: Is it me, or is it my hormones? – Woodinville Northwest News

The endocrine or hormone system of the body is an interesting thing. When one hormone is off balance, it seems to throw the whole body out of order. When hormones are not in alignment, it can effect mood, energy, weight, inflammation, blood sugar balance, body pain, sleep and more.

The female hormones are the most common type of hormone imbalance. Premenstrual or peri-menopausal symptoms can present with heavier menstruation, increased depression and anxiety, and trouble sleeping. Many times, estrogen may become more dominant in relation to the progesterone. This can create symptoms like migraine headaches, weight gain and heavy bleeding which leads to anemia and fatigue.

Androgenic hormones like testosterone and DHEA can be off balance in men and also women. In excess, this can cause anger, irritability, increased hair growth and acne. When these hormones drop too low, it can cause low libido, hair loss, fatigue, foggy brain and symptoms of depression. Lack of exercise and diet may be related to changing androgen hormones as well as increased stress. A simple blood test can help rule determine the values of hormones.

The thyroid is also connected to the endocrine system. The thyroid sits on the neck and is responsible for metabolism. When it runs too slow, the bowels can tend towards constipation, the energy drops low, and mood can be effected as well as hair loss. Similar symptoms arise when the cortisol hormone is too low, which is part of the stress response system. I think just about everyone has had stress over the last two years.

Other conditions that may mimic hormones include depression, vitamin deficiencies, anemia, and chronic disease. There are treatments for hormone imbalances including herbal nutrients, diet and lifestyle recommendations, and using actual hormones to replace what the body needs. Having a thorough workup from your doctor is important with anything going on, so a good quality treatment plan can be established. You may be surprised by what we find!

Dr. Allison Apfelbaum is a primary care Naturopathic doctor at Tree of Health medicine in Woodinville, WA. To learn more go towww.treeofhealthmedicine.com.

View post:

Tree of Health Medicine: Is it me, or is it my hormones? - Woodinville Northwest News

Biosimilars Market is estimated to value over USD 91 Billion by 2030 | MDC Research Study – GlobeNewswire

Pune, April 05, 2022 (GLOBE NEWSWIRE) -- The globalbiosimilars market is driven by cost effectiveness of drug due to which there is a increase demand of biosimilar drugs. Moreover, diverse applications of biosimilars for treatment of several chronic ailments, namely cancer and diabetes is anticipated to further contribute significantly to growing demand of this products in the coming years. Furthermore the collaboration are in a strategic manner which result in enhanced productivity and clinical trials. However, availability of affordable generic drugs, and complexity involved in the process of manufacturing are likely to restrain the market to a certain extent.

Biosimilars Market by Type of Manufacturing

On the basis of type of manufacturing, the market can be segmented into in-house manufacturing and contract manufacturing. In terms of market share, the segment of in-house manufacturing accounted for the largest share, as in-house manufacturing reduces costs associated with shipping, delivery and thereby lowering the overall cost of manufacturing.

Biosimilars Market by Diseases

Similarly, in terms of diseases the biosimilars market can be segmented into chronic disease, oncology, autoimmune disease, blood disorders, infectious diseases, growth hormone deficiency and other diseases. The blood disorder segment accounted for the largest share of the market, owing to low cost of biosimilars as compared to biologics, and rising incidence of blood disorders worldwide among others.

Get a Sample Copy of the Reporthttps://www.marketdatacentre.com/sample/61

Biosimilars Market by Regions

The global biosimilars market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). Europe dominated the market, followed by North America and Asia Pacific. Asia Pacific is expected to dominate the global market in the forecast period. Factors such as the patent expiry of launch of new biosimilars, biologic products, rising incidence of chronic disorders, and emergence of new marketplayers are anticipated to drive market growth in this region

Biosimilars Market Prominent Players

The prominent players in the global biosimilars market are Pfizer, Sandoz International, Teva Pharmaceuticals, Amgen, Biocon, Dr. Reddys Laboratories, Celltrion, Samsung Biologics, Stada Arzneimittel AG, and Mylan.

Vendor Assessment

Vendor assessment includes a deep analysis of how vendors are addressing the demand in the Elisa Analyzers Market. The MDC CompetetiveScape model was used to assess qualitative and quantitative insights in this assessment. MDC's CompetitiveScape is a structured method for identifying key players and outlining their strengths, relevant characteristics, and outreach strategy. MDC's CompetitiveScape allows organizations to analyze the environmental factors that influence their business, set goals, and identify new marketing strategies. MDC Research analysts conduct a thorough investigation of vendors' solutions, services, programs, marketing, organization size, geographic focus, type of organization and strategies.

Speak to Analysthttps://www.marketdatacentre.com/analyst/61

Technology Assessment

Technology dramatically impacts business productivity, growth and efficiency.Technologies can help companies develop competitive advantages, but choosing them can be one of the most demanding decisions for businesses. Technology assessment helps organizations to understand their current situation with respect to technology and offer a roadmap where they might want to go and scale their business. A well-defined process to assess and select technology solutions can help organizations reduce risk, achieve objectives, identify the problem, and solve it in the right way. Technology assessment can help businesses identify which technologies to invest in, meet industry standards, compete against competitors.

Business Ecosystem Analysis

Advancements in technology and digitalization have changed the way companies do business; the concept of a business ecosystem helps businesses understand how to thrive in this changing environment. Business ecosystems provide organizations with opportunities to integrate technology in their daily business operations and improve research and business competency. The business ecosystem includes a network of interlinked companies that compete and cooperate to increase sales, improve profitability, and succeed in their markets. An ecosystem analysis is a business network analysis that includes the relationships amongst suppliers, distributors, and end-users in delivering a product or service.

Regions and Countries Covered

North America (US, Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and Rest of the World (RoW)

Report Coverage

Elisa Analyzers Market Dynamics, Covid-19 Impact on the Elisa Analyzers Market, Vendor Profiles, Vendor Assessment, Strategies, Technology Assessment, Product Mapping, Industry Outlook, Economic Analysis, Segmental Analysis, Elisa Analyzers Market Sizing, Analysis Tables

Vendor Profiles Covered

All Major Tier-1, Tier-2, and Tier-3 companies are covered in this Elisa Analyzers Market report (25 Vendor Profiles)

At MDC Research, we offer research solutions to help businesses break the barriers of doubt or uncertainties when they plan to expand their growth. Our researchers compile data and information that help chief executive officers decide which growth opportunities in a market to pursue.

MDC Research is known for conducting well-researched reports, and the expertise of our researchers contributes to the outstanding quality of our reports. MDC Research enables businesses to make impactful decisions by blending innovation and analytical thinking. Our unique blend of these two skills assures you access to the most complete and up-to-date information about your industry.

MDC Research has a wealth of experience using the latest methodologies to develop reports for a wide range of clients in diverse markets. Our commitment to delivering high-quality research and creating innovative reports is one of the reasons why MDC Research is such a trusted name in the business world today.

Read Overview of the Reporthttps://www.marketdatacentre.com/biosimilars-market-61

About MDC:

Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited)

Market Data Centre offers complete solutions for market research reports in miscellaneous businesses.These decisions making process depend on wider and systematic extremely important information created through extensive study as well as the most recent trends going on in the industry.The company also attempts to offer much better customer-friendly services and appropriate business information to achieve our clients ideas.

See original here:

Biosimilars Market is estimated to value over USD 91 Billion by 2030 | MDC Research Study - GlobeNewswire

NovaXS Biotech wants to make injection therapy needle-free – TechCrunch

A startup spawned from a lab at the University of California, Berkeley has won investor support to work on its patented needle-free injector, which it hopes can make therapies that traditionally require daily self-administered medicines less painful.

NovaXS Biotech, founded by 21-year-old Berkeley researcher Alina Su in 2020, is seeking a $1.5 million seed round with the commitment of several investors already: Courtyard Ventures, a fund focused on UC Berkeley startups, MHub Impact Fund, an innovation hub based out of Chicago, medical device maker Baxter, and Edward Elmhurst Health, an integrated health system in Illinois. Chinese venture capital firm NewGen VC has also joined the round. AiBasis, an investment firm led by Baidu co-founder Lei Ming, and Boston-based Taihill Venture have expressed great interest but havent invested, according to Su.

NovaXSs injection gun, which patients can snuggly hold in their hand, can push biologics into the bodys subcutaneous and intramuscular level within 0.3 seconds using liquid pressure. The device also comes with a cloud-based platform that collects patient information for physicians, like injection time, frequency, dosage volume, and medication temperature.

The startup has found two early use cases already in vitro fertilization and drug delivery for Duchenne muscular dystrophy (DMD). Su is particularly passionate about the treatment of the latter. DMD, an inherited disease caused by defects in a gene that encodes the protein critical to muscle functions, can put patients in wheelchairs by the age of 12. There is an existing FDA-approved solution that uses an Adeno-associated virus (AAV) to deliver modified genetic material to cells impacted, but the treatment can potentially generate adverse side effects.

Recent advancement in gene-editing technology has given the once incurable disease new hope, though much needs to be done to actually turn the lab work into commercially viable solutions. Thats what NovaXS aspires to do, with Su bringing her bioengineering professor Irina Conboys gene-editing CRISPR therapies to DMD patients using the startups needle-less injector.

Many large pharmaceutical companies lack the incentive to fund IVF or rare disease R&D because these specific markets have limited patients. On the other hand, smaller companies are lacking the resources to tackle such daunting tasks, said Su.

NovaXS is targeting gene therapy and IVF at the initial phase because Su believes they have the biggest potential to acquire a large market share. Its also planning to work on other diseases that require in-home injections, such as diabetes and growth hormone disorders in children.

When the seed round closes, NovaX plans to work on the safety and stability of its products, apply for FDA clearance, and put together its core management team.

Originally from China, Sus other goal is to bring DMD gene therapies to her home country. The startup will still be headquartered in the US but conducting clinical trials for the DMD treatment in China, where local governments are luring foreign and returning science and technology talents with attractive money and policy support.

Unlike in contested arenas like semiconductors and artificial intelligence, where tech transfers between the US and China are increasingly restricted, Su reckoned that in medicines and healthcare, the two superpowers are incentivized to collaborate because of a larger pool of clinical data is the basic staple of medical advancements.

We dont want our research to just get published in Nature. We want it to be helping people in real life, Su said.

The business prospects of cutting-edge and still evolving technology like gene editing therapies can be hard to predict, and the Theranos saga has only made venture capitalists more prudent about esoteric medicines. But Su saw a silver lining.

The problem of Theranos isnt its business but its science. We are not short of great scientists, but we dont have enough medical talent who also understands business. We hope to fill the gap.

Update on April 5: NovaXS told TechCrunch earlier that the funding round has closed. The investment has not closed, and the company is still in discussion with AiBasis and Taihill. The article has been updated to reflect that.

Read the rest here:

NovaXS Biotech wants to make injection therapy needle-free - TechCrunch